3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
787
INDUSTRY
337
NIH
87
NETWORK
46
OTHER_GOV
16
FED
4
UNKNOWN
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
36
Stomach Neoplasms
19
Esophageal Neoplasms
17
Carcinoma, Non-Small-Cell Lung
13
Colorectal Neoplasms
12
Rectal Neoplasms
11
Triple Negative Breast Neoplasms
9
Lung Neoplasms
8
Brain Neoplasms
8
Small Cell Lung Carcinoma
7
Squamous Cell Carcinoma of Head and Neck
6
Neoplasms
6
Neoplasm Metastasis
6
Esophageal Squamous Cell Carcinoma
6
Nasopharyngeal Carcinoma
5
Melanoma
4
Lymphoma, Extranodal NK-T-Cell
4
Carcinoma, Hepatocellular
4
Uterine Cervical Neoplasms
3
Recurrence
3
Meningeal Carcinomatosis
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Head and Neck Neoplasms
3
Colonic Neoplasms
3
Vomiting
2
Urinary Bladder Neoplasms
2
Skin Diseases
2
Sarcoma
2
Interventions
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
UNKNOWN
×
Interventional
×
Urinary Bladder Neoplasms
×
Clear all
NCT02346955
2020-08-27
MK-6018-001
KitovPharma
Phase 1
Terminated
27 enrolled
NCT03672240
2020-07-20
NMIBC
AsierisPharma
Phase 1/2
Completed
6 enrolled